NextCure, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunomedicines for the treatment of cancer and other immune-related diseases. The company's mission is to revolutionize cancer treatment by restoring normal immune function, particularly for patients who do not respond to current therapies or whose cancer progresses despite treatment. Headquartered in Beltsville, Maryland, NextCure aims to become a global leader in innovative immunomedicines through scientific advancement and a focus on patient needs.

Utilizing its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO™) platform, NextCure identifies novel immune targets and develops next-generation immunotherapies, including antibody-drug conjugates (ADCs) and fusion proteins. Key clinical-stage candidates in its pipeline include SIM0505, an ADC targeting CDH6 for solid tumors, which is currently in Phase 1 clinical testing in the U.S. and China and has received FDA Fast Track designation for platinum-resistant ovarian cancer. Another significant program is LNCB74, an ADC targeting B7-H4 for various tumor types, also in Phase 1 clinical development. The company is also exploring partnering opportunities for other programs, such as NC410, a LAIR-2 fusion protein, and preclinical candidates like NC181 for Alzheimer's disease and NC605 for brittle bone disease.

Led by President and CEO Michael Richman, who co-founded the company in 2015, NextCure is actively advancing its pipeline. Recent notable developments include the FDA granting Fast Track designation to SIM0505 in April 2026 and the planned presentation of its Phase 1 data at ASCO 2026. The company expanded the Phase 1 trial of SIM0505 into the United States in October 2025 and secured approximately $21.5 million in gross proceeds from a private placement PIPE in November 2025. NextCure has been strategically reprioritizing its resources to focus on its promising ADC programs, with current financial resources expected to fund operations into the first half of 2027.